- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01517893
Clinical Trial of Simvastatin to Treat Generalized Vitiligo
A Phase-II, Randomized, Placebo-controlled Trial of Simvastatin in Generalized Vitiligo
Study Overview
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Massachusetts
-
Worcester, Massachusetts, United States, 01655
- University of Massachusetts Medical School Clinical Research Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- male gender
- ages 18-64
- at least one vitiligo skin lesion measuring at least 2x2 cm in size
- willing and able to understand and sign informed consent
- able to complete study and comply with study procedures
Exclusion Criteria:
- history of segmental vitiligo
- allergy to statin medications
- use of statin medications due to cardiac risks.
- use of any medications contraindicated with use of simvastatin
- use of topical vitiligo treatments in past 4 weeks
- use of laser or light-based vitiligo treatments within the past 8 weeks
- treatment with immunomodulating oral medications in the past 4 weeks
- use of statin medications in the past 8 weeks
- evidence of hepatic dysfunction, personal or family history of non-alcoholic steatotic hepatitis, or personal history of hepatitis
- evidence of renal dysfunction
- history of myopathy or rhabdomyolysis, or elevated baseline creatinine kinase
- recent history of alcohol or drug abuse
- history of diabetes
- untreated hypothyroidism
- other conditions that require the use of interfering topical or systemic therapy
- other current conditions that might interfere with study assessments such as, but not limited to, atopic dermatitis and psoriasis
- clinically significant abnormal findings or conditions which might, in the opinion of the Principal Investigator, interfere with study evaluations or pose a risk to subject safety during the study.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Intervention arm
Sig: Simvastatin 40 mg, increased to 80 mg after 1 month if initial dose tolerated
|
Sig: 40 mg PO daily for 1 month, increased to 80 mg PO daily for 5 months if low dose tolerated
|
Placebo Comparator: Placebo Arm
Sig: 40 mg PO daily for 1 month, increased to 80 mg PO daily for 5 months if low dose tolerated
|
Sig: 40 mg PO daily for 1 month, increased to 80 mg PO daily for 5 months if low dose tolerated
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Participants With a Decrease in Vitiligo Area Scoring Index (VASI) Score
Time Frame: Assessed at baseline and final study visit, 6 months after randomization
|
Number of participants with 33% decrease in the Vitiligo Area Scoring Index (VASI) from baseline to the last available study visit. Decrease in VASI score means improvement. Minimum value is 0, that means no vitiligo. maximum value is 100, that means 100% of the body surface area has vitiligo (total body surface area). |
Assessed at baseline and final study visit, 6 months after randomization
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Participants With Increase in Investigator's Global Assessment Score
Time Frame: Assessed at baseline and final study visit, 6 months after randomization
|
Increase in Investigator Global Assessment Scores of 30% or more from baseline to last available visit. Increase in score means improvement. 0% is no improvement at all. 100% is complete recovery. |
Assessed at baseline and final study visit, 6 months after randomization
|
Number of Participants Experiencing Toxicity From of High-dose Simvastatin .
Time Frame: Assessed at baseline, then monthly until final study visit, six months after randomization.
|
The number of participants who experienced toxicity based upon monitored lab values (Liver Function Test) and patient symptoms for evidence of simvastatin toxicity
|
Assessed at baseline, then monthly until final study visit, six months after randomization.
|
Change in Sentinel Patch Area
Time Frame: Assessed at baseline and final study visit, 6 months after randomization
|
Change in percent depigmentation of sentinel patch lesion from baseline to last available study visit ( 6 months after randomization). positive numbers mean increase or worsening of sentinel patch area negative numbers mean decrease or improvement of sentinel patch area |
Assessed at baseline and final study visit, 6 months after randomization
|
Change in Quality of Life Score by Using DERMATOLOGY LIFE QUALITY INDEX (DLQI)
Time Frame: Assessed at baseline and final study visit, 6 months after randomization
|
The aim of this questionnaire is to measure how much your skin problem has affected your life. We measured change in questionnaire score from baseline to end of study (at 6 months after randomization) of subjects randomized to treatment with simvastatin versus placebo. Change was measured as a drop in score at the end of 6 months of treatment. Minimum score is 0, maximum is 30. Higher value means worse score. |
Assessed at baseline and final study visit, 6 months after randomization
|
Number of Participants With an Increase in Patient's Global Assessment Score
Time Frame: Assessed at baseline and final study visit, 6 months after randomization
|
Increase in Patient's Global Assessment Scores of 30% or more from baseline to last available visit Increase means improvement.
minimum is 0% and maximum is 100%
|
Assessed at baseline and final study visit, 6 months after randomization
|
Serum CXCL10 Levels From the First and Last Available Clinic Visits Were Measured Via ELISA
Time Frame: Assessed at baseline and final study visit, 6 months after randomization
|
Determination of the effects of simvastatin treatment on Serum CXCL10 levels from the first and last available clinic visits were measured via ELISA in the blood of patients with vitiligo treated with simvastatin versus placebo
|
Assessed at baseline and final study visit, 6 months after randomization
|
CXCR3 Expression on CD8+ T Cells
Time Frame: Assessed prior to treatment and periodically while on treatment
|
Determination of the effects of simvastatin treatment on CXCR3 expression in melanocyte-specific, autoreactive CD8+ T cells in the blood of patients with vitiligo treated with simvastatin versus placebo
|
Assessed prior to treatment and periodically while on treatment
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: John E. Harris, MD, PhD, University of Massachusetts, Worcester
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- UM-DERM001
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Vitiligo
-
PfizerRecruitingStable Nonsegmental Vitiligo | Active Nonsegmental VitiligoUnited States, Spain, Australia, Mexico, Canada, China, Japan, Italy, Turkey, Korea, Republic of, Germany, South Africa, Poland, United Kingdom, Bulgaria
-
PfizerRecruitingStable Nonsegmental Vitiligo | Active Nonsegmental VitiligoJapan, Canada, China, United States
-
Fundació Institut de Recerca de l'Hospital de la...Completed
-
Incyte CorporationRecruitingNonSegmental VitiligoGermany, United States, Italy, Poland, Canada, France, Bulgaria, Hungary, United Kingdom
-
Incyte CorporationCompletedNonSegmental VitiligoUnited States, Canada
-
Cairo UniversitySuspended
-
Assiut UniversityUnknown
-
University of TorontoCanadian Interdisciplinary Network Complementary & Alternative Medicine ResearchCompleted
-
University Hospital, GhentNovartisCompletedVitiligo VulgarisBelgium
Clinical Trials on Simvastatin
-
University of CopenhagenCompletedCardiovascular Disease | Diabetes MellitusDenmark
-
dr.Frank L.J. VisserenMerck Sharp & Dohme LLCCompletedThe PostprAndial eNdothelial Function After Combination of Ezetimibe and simvAstatin Study (PANACEA)Metabolic SyndromeNetherlands, Spain
-
Organon and CoCompletedMyocardial Infarction | Hypercholesterolemia
-
University of Sao PauloCompletedCoronary Heart Disease
-
University of Maryland, BaltimoreMerck Sharp & Dohme LLCCompletedMetabolic SyndromeUnited States
-
Peking Union Medical College HospitalUnknownAtherosclerosisChina
-
Organon and CoCompletedHypercholesterolemia
-
Hue University of Medicine and PharmacyUniversità degli Studi di SassariUnknownChronic Kidney Diseases | HypercholesterolemiaVietnam
-
Organon and CoCompleted
-
Federal State Budgetary Scientific Institution,...Completed